Continuous associations of type 2 biomarkers and efficacy of dupilumab in children with uncontrolled, moderate-to-severe asthma
L. Bacharier (Nashville, TN, United States), D. Jackson (Madison, WI, United States), I. Pavord (Oxford, United Kingdom), J. Maspero (Buenos Aires, Argentina), A. Fiocchi (Rome, Italy), X. Mao (Bridgewater, NJ, United States), J. Jacob-Nara (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States), E. Laws (Bridgewater, NJ, United States), L. Mannent (Chilly-Mazarin, France), B. Akinlade (Tarrytown, NY, United States), H. Staudinger (Bridgewater, NJ, United States), D. Lederer (Tarrytown, NY, United States), M. Hardin (Cambridge, MA, United States)
Source: International Congress 2022 – New insights into paediatric asthma diagnosis and management of severe asthma
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Bacharier (Nashville, TN, United States), D. Jackson (Madison, WI, United States), I. Pavord (Oxford, United Kingdom), J. Maspero (Buenos Aires, Argentina), A. Fiocchi (Rome, Italy), X. Mao (Bridgewater, NJ, United States), J. Jacob-Nara (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States), E. Laws (Bridgewater, NJ, United States), L. Mannent (Chilly-Mazarin, France), B. Akinlade (Tarrytown, NY, United States), H. Staudinger (Bridgewater, NJ, United States), D. Lederer (Tarrytown, NY, United States), M. Hardin (Cambridge, MA, United States). Continuous associations of type 2 biomarkers and efficacy of dupilumab in children with uncontrolled, moderate-to-severe asthma. 2952
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|